Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Alexander Staab"'
Autor:
Jörg Lippert, Rolf Burghaus, Andrea Edginton, Sebastian Frechen, Mats Karlsson, Andreas Kovar, Thorsten Lehr, Peter Milligan, Valerie Nock, Sergej Ramusovic, Matthew Riggs, Stephan Schaller, Jan Schlender, Stephan Schmidt, Michaël Sevestre, Erik Sjögren, Juri Solodenko, Alexander Staab, Donato Teutonico
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 12, Pp 878-882 (2019)
Externí odkaz:
https://doaj.org/article/bdd5616c4719420aa5b5c08de592ba8c
Autor:
Yusuke Tadayasu, Akiko Sarashina, Yasuhiro Tsuda, Shinji Tatami, Christian Friedrich, Silke Retlich, Alexander Staab, Mikihisa Takano
Publikováno v:
Journal of Pharmacy & Pharmaceutical Sciences, Vol 16, Iss 5 (2013)
[Objectives] Linagliptin is a novel, highly selective and long acting DPP-4 inhibitor for the treatment of type 2 diabetes mellitus (T2DM). Linagliptin exhibits non-linear pharmacokinetics (PK) due to saturable binding to plasma and tissue DPP-4. The
Externí odkaz:
https://doaj.org/article/37eb091a6ac9429eaede04e474fe5e78
Autor:
Sergej Ramusovic, Thorsten Lehr, Joerg Lippert, Stephan Schmidt, Mats O. Karlsson, Matthew M. Riggs, Peter A. Milligan, Juri Solodenko, Sebastian Frechen, Erik Sjögren, Donato Teutonico, Stephan Schaller, Michael Sevestre, Rolf Burghaus, Andreas Kovar, Valerie Nock, Jan Schlender, Alexander Staab, Andrea N. Edginton
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 12, Pp 878-882 (2019)
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology
Systems pharmacology integrates structural biological and pharmacological knowledge and experimental data, enabling dissection of organism and drug properties and providing excellent predictivity. The development of systems pharmacology models is a s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::159c6e2733bb84f0f5960b9c2ef63082
https://doaj.org/article/bdd5616c4719420aa5b5c08de592ba8c
https://doaj.org/article/bdd5616c4719420aa5b5c08de592ba8c
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology
Models were developed to characterize the relationship between afatinib exposure and diarrhea and rash/acne adverse event (AE) trajectories, and their predictive ability was assessed. Based on pooled data from seven phase II/III clinical studies incl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a016b07cc0b5263799f1f6b1f47a3e5f
https://doi.org/10.1002/psp4.12384
https://doi.org/10.1002/psp4.12384
Autor:
Rajanikanth Madabushi, Kevin Krudys, Alexander Staab, Scott Marshall, Efthymios Manolis, Sandra A.G. Visser, Kevin Dykstra
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology
Good practices around model-informed drug discovery and development (MID3) aim to improve the implementation, standardization, and acceptance of these approaches within drug development and regulatory review. A survey targeted to clinical pharmacolog
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d9f0c1a05c3f1aead8020cd1481fe67
https://doi.org/10.1002/psp4.12372
https://doi.org/10.1002/psp4.12372
Publikováno v:
British Journal of Clinical Pharmacology. 82:739-753
Aims Olodaterol is an orally inhaled β2-agonist for treatment of chronic obstructive pulmonary disease (COPD). The aims of this population pharmacokinetic (PK) analysis were: (1) to investigate systemic PK and thereby make inferences about pulmonary
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d7c702044beaddcf92156182eba2fae
https://doi.org/10.1111/bcp.12999
https://doi.org/10.1111/bcp.12999
Autor:
S Rohou, JL Steimer, Thomas Kerbusch, Bengt Hamrén, O DellaPasqua, Jörg Lippert, Alexander Staab, C Tornøe, F Ivanow, Marylore Chenel, Lutz Harnisch, Sag Visser, V Cosson, Rolf Burghaus, N Frey, Scott Marshall, Peter A. Milligan, Sya Cheung
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology. 5:93-122
This document was developed to enable greater consistency in the practice, application, and documentation of Model-Informed Drug Discovery and Development (MID3) across the pharmaceutical industry. A collection of "good practice" recommendations are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7d06d1e48f6875a7c4d6d71a60068f1f
https://doi.org/10.1002/psp4.12049
https://doi.org/10.1002/psp4.12049
Autor:
Jens Markus Borghardt, Christina Kunz, Stephan Formella, Charlotte Kloft, Benjamin Weber, Alexander Staab
Publikováno v:
British Journal of Clinical Pharmacology. 81:538-552
Aims Olodaterol, a novel β2-adrenergic receptor agonist, is a long-acting, once-daily inhaled bronchodilator approved for the treatment of chronic obstructive pulmonary disease. The aim of the present study was to describe the plasma and urine pharm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::adc384f92d27487fbf1692f34419f07a
https://doi.org/10.1111/bcp.12780
https://doi.org/10.1111/bcp.12780
Autor:
Sanjay Patel, Ulrike Graefe-Mody, Vincent Duval, Ulrich Jaehde, Silke Retlich, Christian Friedrich, Alexander Staab
Publikováno v:
Clinical Pharmacokinetics
Background and Objectives Linagliptin is a dipeptidyl peptidase (DPP)-4 inhibitor, used to treat type 2 diabetes mellitus (T2DM). Population pharmacokinetic and pharmacodynamic analyses were performed to characterize the impact of clinically relevant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0706a5704b106ba8842416e0f5c05689
https://doi.org/10.1007/s40262-014-0232-4
https://doi.org/10.1007/s40262-014-0232-4
Autor:
Leo Seman, Thomas R. MacGregor, Sreeraj Macha, Marc R. Gastonguay, William R. Gillespie, Hans-Juergen Woerle, Matthew M. Riggs, Alexander Staab
Publikováno v:
British Journal of Clinical Pharmacology. 78:1407-1418
Aims To provide model-based clinical development decision support including dose selection guidance for empagliflozin, an orally administered sodium glucose cotransporter 2 inhibitor, through developed exposure−response (E−R) models for efficacy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ec49f7aa1c23fb042a63216107d3bf6e
https://doi.org/10.1111/bcp.12453
https://doi.org/10.1111/bcp.12453